A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer - Liu, Joyce F.; Brady, Mark F.; Matulonis, Ursula A.; Miller, Austin; Kohn, Elise C.; Swisher, Elizabeth M.; Tew, William P.; Cloven, Noelle Gillette; Muller, Carolyn; Bender, David; Moore, Richard G.; Michelin, David Paul; et al. (Journal of clinical oncology, 2020)